Development of anti-obesity agents: Drugs that target neuropeptide and neurotransmitter systems

Expert Opinion on Investigational Drugs

Volumn 17, Issue 3, 2008, Pages 321-325

  Fong, Tung M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Energy balance; Neuropeptide; Neurotransmitter; Obesity; Pharmacotherapy

Indexed keywords

ANTIOBESITY AGENT; APD 356; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABIS; CHOLECYSTOKININ A RECEPTOR; GI 181771; LEPTIN; MK 0557; NEUROPEPTIDE RECEPTOR; NEUROPEPTIDE Y RECEPTOR; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; NEUROTRANSMITTER RECEPTOR; NORFENFLURAMINE; PEPTIDE YY [3-36]; RIMONABANT; SEROTONIN 2C RECEPTOR; SIBUTRAMINE; TARANABANT; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERANCE; DRUG TREATMENT FAILURE; ENERGY CONSUMPTION; ENERGY EXPENDITURE; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; LOW DRUG DOSE; METABOLIC DISORDER; NAUSEA; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; REPEATED DRUG DOSE; REVIEW; UNSPECIFIED SIDE EFFECT; VALVULAR HEART DISEASE; VOMITING; WEIGHT REDUCTION; BRAIN; DRUG DESIGN; DRUG EFFECT; METABOLISM;

ANTI-OBESITY AGENTS; BRAIN; DRUG DESIGN; HUMANS; OBESITY; RECEPTORS, NEUROPEPTIDE; RECEPTORS, NEUROTRANSMITTER;

EID: 40949124705     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.17.3.321     Document Type: Review

References (40)

1. Parker E, Van Heek M, Stamford A. Neuropeptide Y receptors as targets for anti-obesity drug development: perspective and current status. Eur J Pharmacol 2002;440:173-87
2. MacNeil DJ, Kanatani A. NPY and energy homeostasis: an opportunity for novel anti-obesity therapies. EXS 2006;95:143-56
3. Ishihara A, Kanatani A, Mashiko S, et al. A neuropeptide Y Y5 antagonist selectively ameliorates body weight gain and associated parameters in diet-induced obese mice. Proc Natl Acad Sci USA 2006;103:7154-8
4. Erondu N, Gantz I, Musser B, et al. Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab 2006;4:275-82
5. Greenberg I, Kuehnle J, Medelson J, Bernstein J. Effects of marijuana use on body weight and caloric intake in humans. Psychopharmacology 1976;49:79-84
6. Hollister LE. Hunger and appetite after single doses of marihuana, alcohol, and dextroamphetamine. Clin Pharmacol Ther 1971;12:44-9
7. Beal JE, Olson R, Laubenstein L, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 1995;10:89-97
8. Di Marzo V, Goparaju SK, Wang L, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001;410:822-5
9. Arnone M, Maruani J, Chaperon F, et al. Selective inhibition of sucrose and ethanol intake by SR141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology 1997;132:104-6
10. Colombo G, Agabio R, Diaz G, et al. Appetite suppression and weight loss after the cannabinoid antagonist SR141716. Life Sci 1998;63:113-7
11. Bouaboula M, Perrachon S, Milligan L, et al. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J Biol Chem 1997;272:22330-9
12. Lin LS, Lanza TJ Jr, Jewell JP, et al. Discovery of N-[(1S,2S)-3-(4- chlorophenyl)-2-(3-cyanophenyl)-l- methylpropyl]-2-methyl-2- {[5(trifluoromethyl)pyridin-2-yl]oxy} propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity. J Med Chem 2006;49:7584-7
13. Fong TM, Guan X-M, Marsh DJ, et al. Anti-obesity efficacy of a novel cannabinoid-1 receptor inverse agonist MK-0364 in rodents. J Pharmacol Exp Ther 2007;321:1013-22
14. Van Gaal LF, Rissanen AM, Scheen AJ, et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients:1-year experience from the RIO-Europe study. Lancet 2005;365:1389-97
15. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353:2121-34
16. Scheen AJ, Finer N, Hollander P, et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006;368:1660-72
17. Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006;295:761-75
18. Stevens C, Cilisssen C, Desmet M, et al. MK-0364, a CBIR inverse agonist, reduces acute food intake in overweight/obese male volunteers. Diabetes 2007;56(Suppl 1):A462
19. Blundell JE, Jebb SA, Stiubbs RJ, et al. Effect of rimonabant on energy intake, motivation to eat and body weight with or without hypocaloric diet: the REBA study. Obes Rev 2006;7(Suppl 2):104
20. Addy C, Wright H, Van Laere K, et al. The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metab 2008;7:68-78
21. Burns HD, Van Laere K, Sanabria-Bohorquez S, et al. [18F] MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proc Natl Acad Sci USA 2007;104:9800-5
22. Bensaid M, Gary-Bobo M, Esclangon A, et al. The cannabinoid CB 1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003;63:908-14
23. Lofgren P, Sjolin E, Wahlen K, Hoffstedt J. Human adipose tissue cannabinoid receptor 1 gene expression is not related to fat cell function or adiponectin level. J Clin Endocrinol Metab 2007;92:1555-9
24. Hamilton B, Allgaeuer S, Getta P, et al. Do adipose tissue cannabinoid CB1 receptor modulate adiponectin expression or lipolysis? Obes Res 2005;13(2005 NAASO Program Abstract Suppl):A162
25. Marsh DJ, Hollopeter G, Huszar D, et al. Response of melanocortin-4 receptor-deficient mice to anorectic and orexigenic peptides. Nat Genet 1999;21:119-22
26. Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002;418:650-4
27. Degen L, Oesch S, Casanova M, et al. Effect of peptide YY3-36 on food intake in humans. Gastroenterology 2005;129:1430-6
28. Tschop M, Castaneda TR, Joost HG, et al. Does gut hormone PYY3-36 decrease food intake in rodents? Nature 2004;430:166-8
29. Kuo LE, Kitlinska JB, Tilan JU, et al. Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nat Med 2007;13:803-11
30. Gantz I, Erondu N, Mallick M, et al. Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults. J Clin Endocrinol Metab 2007;92:1754-7
31. Illum L. Is nose-to-brain transport of drugs in man a reality? J Pharm Pharmacol 2004;56:3-17
32. Costantino HR, Illum L, Brandt G, et al. Intranasal delivery: physicochemical and therapeutic aspects. Int J Pharm 2007;337:1-24
33. Gibbs J, Young RC, Smith GP, Cholecystokinin decreases food intake in rats. J Comp Physiol Psychol 1973;84:488-95
34. Stacher G, Steinringer H, Schmierer G, et al. Cholecystokinin octapeptide decreases intake of solid food in man. Peptides 1982;3:133-6
35. West DB, Fey D, Woods SC. Cholecystokinin persistently suppresses meal size but not food intake in free-feeding rats. Am J Physiol 1984;246:R776-87
36. Jordan J, Greenway FL, Leiter LA, et al. Stimulation of cholecystokinin-A receptors with GI181771X does not cause weight loss in overweight or obese patients. Mol Ther 2008;83:281-7
37. Castillo EJ, Delgado-Aros S, Camilleri M, et al. Effect of oral CCK-1 agonist GI181771X on fasting and postprandial gastric functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol 2004;287:G363-9
38. Bjening C, Williams J, Whelan K, et al. Chronic oral administration of APD356 significantly reduces body weight and fat mass in obesity-prone male and female rats. Int J Obesity 2004;28(1 Suppl):214s
39. Smith S, Prosser W, Donahue D, et al. APD356, an orally-active selective 5HT2c agonist, reduces body weight in obese adult men and women. Diabetes 2006;55(Suppl 1):344-OR
40. Hopkins PN, Polukoff GI. Risk of valvular heart disease associated with use of fenfluramine. BMC Cardiovasc Disord 2003;3:5-18